Disclosure RO reports personal fees for advisory board membership of Bristol Myers Squibb (BMS) and Servier; personal fees as an invited speaker from Merck Serono and Merck Sharp & Dohme (MSD) and a non-remunerated leadership role with Czecrin. MA reports personal fees for advisory board membership of BMS, Lilly, MSD and Servier and a nonremunerated role as principal investigator (PI) of the investigator-initiated trial with Merck Serono. AC reports fees paid to his institution as an invited speaker from Amgen, Foundation Medicine, Merck Serono and Roche; fees paid to his institution for advisory board membership of Amgen, AnHeart Therapeutics, Merck Serono, Roche and Transgene; personal fees for an editorial role as an Associate Editor for Annals of Oncology and ESMO Open and editor for Cancer Treatment Reviews; institutional funding as PI from Actuate Therapeutic, Adaptimmune, amcure, Amgen, Astellas, AstraZeneca, Bayer, BeiGene, Bristol Myers Squibb (BMS), FibroGen, Genentech, Lilly, MedImmune, Merck Serono, MSD, Natera, Novartis, Servier, Sierra Oncology and Takeda and non-remunerated role as General and Scientific Director of INCLIVA Biomedical Research Institute. TL reports non-remunerated roles as President and Board Chair of the Trans-Tasman Radiation Oncology Group (TROG), Board Director and Company Secretary of Australasian Gastrointestinal Trials Group (AGITG), Global trial chair for TOPGEAR, an Intergroup randomised phase III trial in gastric cancer being conducted by AGITG/TROG/European Organisation for Research and Treatment of Cancer (EORTC)/Canadian Cancer Trials Group (CCTG), Councillor of the Royal Australian and New Zealand College of Radiologists (RANZCR) and Councillor of the International Gastric Cancer Association (IGCA). FL reports personal fees for advisory board membership of Amgen, Astellas Pharma, BMS, Bayer, BeiGene, BioNTech, Eli Lilly, MSD, Novartis, Roche and Daiichi-Sankyo; personal fees as an invited speaker for AstraZeneca, BMS, Eli Lilly, Imedex, Incyte, MedUpdate, Medscape, Merck Serono, MSD, Roche, Servier and StreamedUp!; personal fees from BioNTech and Elsevier for expert testimony; personal fees for writing engagements for Deutscher Ärzteverlag, iOMEDICO and Springer-Nature and a research grant paid to his institute from BMS. MN reports personal fees as an invited speaker at the Medtronic-sponsored Taiwan Thoracic Surgery Society 2021; fees paid to his institute for advisory board membership of Affibody, BMS and BeiGene and participation in the Medtronic-sponsored European Minimally Invasive Esophagectomy (MIO) Thinktank. NCTvG reports fees paid to her institute for advisory board membership of BMS, Diaceutics and Merck/MSD and fees as an invited speaker for MEDtalks. She has also reported non-remunerated activities for an advisory role to the Dutch Cancer Society and the Sacha Swarttouw-Hijmans Foundation. AV reports personal fees for speaker, consultancy and advisory roles for AstraZeneca, Amgen, Basilea, BeiGene, Bayer, Boehringer Mannheim, Bristol-Myers Squibb (BMS), BTG, Daiichi-Sankyo, Eisai, GlaxoSmithKline (GSK), Imaging Equipment Ltd (AAA), Incyte, Ipsen, Jiangsu Hengrui Medicine, MSD, Pierre Fabre, Roche, Sanofi, Servier, Sirtex, Tahio and Terumo; research funding from Incyte and Servier; and participation in educational activities for OncLive and Oncowissen.de. ECS reports personal fees as an invited speaker from Amgen, BMS, Imedex, Merck, Novartis, Prova Education, Servier and touchIME; personal fees for advisory board membership of Astellas, AstraZeneca, BMS, My Personal Therapeutics, Novartis, Roche and Zymeworks; other personal fees from Amgen Trial Steering Group (TSC), BeiGene and Zymeworks for Independent Data Monitoring Committee (IDMC) membership, BMS for expert testimony, Everest Clinical Research as IDMC chair; institutional funding as a local or coordinating PI for clinical trial research from AstraZeneca, Basilea, Daiichi Sankyo, Roche, Merus and MSD and a research grant to her institute from BMS.